Why Tekmira Pharmaceuticals (TKMR) Stock Is Down Today

NEW YORK (TheStreet) -- Tekmira Pharmaceuticals  (TKMR) plunged Monday amid reports that Novartis  (NVS) is closing a significant portion of its RNAi research endeavors in Boston.

FierceBiotech reported the pharmaceutical giant's confirmation that ongoing problems in delivering such therapies tied to the limited number of potential relevant targets led to the move. 

"We have decided to significantly reduce our internal drug discovery efforts in RNA therapeutics," Novartis told FierceBiotech in a statement. "This decision was driven by ongoing challenges with formulation and delivery and the reality that the current range of medically relevant targets where siRNA may be used is quite narrow. In the future we will have a small group working in this field and look for partnering opportunities."

Tekmira suffered in the wake of the news, as it is involved in RNAi drug development. The stock plunged more than 18% to hit a low of $15.02 for the day as of 3:03 p.m. on Monday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TKMR Chart

TKMR data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

3 Stocks Pushing The Drugs Industry Lower

Tekmira Pharmaceuticals (TKMR) Weak On High Volume

Tekmira Pharmaceuticals (TKMR): Today's Weak On High Volume Stock

'Mad Money' Lightning Round: Buy, Buy, Buy Yahoo!, Not Alibaba

Jim Cramer's 'Mad Money' Recap: 'Hit and Run' Investors Are the Worst